This 2009 randomized, double-blind, placebo-controlled trial assessed the effects of chromium picolinate (CrPic) supplementation (1000 μg/day) over 16 weeks in 63 obese nondiabetic adults with metabolic syndrome. The primary outcome, insulin sensitivity index, showed no significant improvement (P = 0.14). While CrPic increased acute insulin response to glucose (P =
